Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of bivalent HPV-16/18 AS04 vaccine in healthy girls and young women from HPV-012
2004-001173-26Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2004
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection and cervical intraepithelial neoplasia (CIN), sponsored by GSK. Primary endpoints: Anti-HPV-16 antibody titers by ELISA, Anti-HPV-18 antibody titers by ELISA and 1 more. Started Aug 2004; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2004-001173-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001173-26.